MX2013006158A - Granulos de dispersion rapida, comprimidos de disolucion oral y metodos. - Google Patents

Granulos de dispersion rapida, comprimidos de disolucion oral y metodos.

Info

Publication number
MX2013006158A
MX2013006158A MX2013006158A MX2013006158A MX2013006158A MX 2013006158 A MX2013006158 A MX 2013006158A MX 2013006158 A MX2013006158 A MX 2013006158A MX 2013006158 A MX2013006158 A MX 2013006158A MX 2013006158 A MX2013006158 A MX 2013006158A
Authority
MX
Mexico
Prior art keywords
rapidly dispersing
dispersing microgranules
orally disintegrating
disintegrating tablets
methods
Prior art date
Application number
MX2013006158A
Other languages
English (en)
Other versions
MX365568B (es
Inventor
Gopi M Venkatesh
Jin-Wang Lai
James M Clevenger
Vijaya Swaminathan
Original Assignee
Aptalis Pharmatech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2013006158(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aptalis Pharmatech Inc filed Critical Aptalis Pharmatech Inc
Publication of MX2013006158A publication Critical patent/MX2013006158A/es
Publication of MX365568B publication Critical patent/MX365568B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se relaciona con microgránulos de rápida dispersión que comprenden al menos un alcohol de azúcar o un sacárido, al menos un súper disgregante y un aditivo farmacéuticamente aceptable con multifunción (por ejemplo, almidón que actúa como aglutinante, disgregante, diluyente/relleno, glidante, etc.) en un nivel bajo que puede formarse no sólo mediante la eliminación de la etapa de trituración en húmedo sino que también evitando la etapa de trituración en seco extensiva. Asimismo, dichos microgránulos de rápida dispersión pueden comprender un agente farmacéuticamente activo proporcionando así una composición farmacéutica o los microgránulos de rápida dispersión producidos son adecuados para su mezcla con un agente farmacéuticamente activo que constituye micropartículas revestidas con gusto enmascarado y/o liberación controlada opcionales para proporcionar una composición farmacéutica y la invención también está dirigida a un método para fabricar dichos microgránulos de rápida dispersión en un rendimiento de utilización alto, así como también comprimidos de desintregación oral que comprenden dichos microgr´´anulso de rápida dispersión también tienen libre circulación.
MX2013006158A 2010-12-02 2011-12-02 Granulos de dispersion rapida, comprimidos de disolucion oral y metodos. MX365568B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41911410P 2010-12-02 2010-12-02
PCT/US2011/063172 WO2012075455A2 (en) 2010-12-02 2011-12-02 Rapidly dispersing granules, orally disintegrating tablets and methods

Publications (2)

Publication Number Publication Date
MX2013006158A true MX2013006158A (es) 2014-03-21
MX365568B MX365568B (es) 2019-06-07

Family

ID=46172602

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006158A MX365568B (es) 2010-12-02 2011-12-02 Granulos de dispersion rapida, comprimidos de disolucion oral y metodos.

Country Status (16)

Country Link
US (1) US20120282335A1 (es)
EP (1) EP2646003B1 (es)
JP (1) JP6014044B2 (es)
KR (1) KR101965002B1 (es)
CN (3) CN108969490A (es)
AU (1) AU2011336300B2 (es)
CA (1) CA2819663C (es)
CL (1) CL2013001586A1 (es)
CO (1) CO6781487A2 (es)
ES (1) ES2813859T3 (es)
MX (1) MX365568B (es)
NZ (1) NZ611467A (es)
RU (1) RU2013127593A (es)
SG (1) SG190448A1 (es)
WO (1) WO2012075455A2 (es)
ZA (1) ZA201304894B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2940931C (en) 2009-10-01 2019-04-30 Adare Pharmaceuticals, Inc. Orally administered corticosteroid compositions
CN108969490A (zh) 2010-12-02 2018-12-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法
JP5656258B2 (ja) * 2011-03-09 2015-01-21 塩野義製薬株式会社 ガランタミンを含有する口腔内崩壊錠剤
WO2014027974A1 (en) * 2012-08-17 2014-02-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating formulation of paliperidone
KR101340733B1 (ko) * 2012-12-31 2013-12-12 (주) 에프엔지리서치 신규한 마이크로그래뉼 제형
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015034678A2 (en) 2013-09-06 2015-03-12 Aptalis Pharmatech, Inc. Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
JP6538063B2 (ja) * 2013-11-05 2019-07-03 シンアジャル コーポレイション 口を介する連続的薬物送達のためのデバイスおよび方法
PL3069733T3 (pl) * 2013-11-13 2023-02-13 National Defense Education And Research Foundation Nowa kompozycja związku stanowiącego acetaminofen niepowodująca w wątrobie działań niepożądanych
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
JP6286690B2 (ja) * 2014-02-20 2018-03-07 フロイント産業株式会社 糖アルコール球形造粒物集合体及びその製造方法、並びに錠剤
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016017711A1 (ja) * 2014-07-30 2016-02-04 持田製薬株式会社 ピラゾール誘導体の製造方法
CN104257653B (zh) * 2014-09-28 2016-08-24 青岛青知企业管理咨询有限公司 一种卡维地洛组合物及其制备方法
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US9867834B2 (en) 2015-06-15 2018-01-16 Banner Life Sciences Llc Non-systemic topical compositions comprising corticosteroids
WO2016205172A1 (en) 2015-06-15 2016-12-22 Banner Life Sciences Llc Soft lozenges comprising corticosteroids
PL3106148T3 (pl) 2015-06-18 2018-08-31 Mithra Pharmaceuticals S A Jednostka dawkowania ulegająca rozpadowi w jamie ustnej zawierająca składnik estetrolowy
PL3310333T3 (pl) 2015-06-18 2020-07-13 Estetra Sprl Ulegająca rozpadowi w jamie ustnej jednostka dawkowana zawierająca składnik estetrolowy
CN105012955B (zh) * 2015-07-30 2017-12-22 湖南尔康制药股份有限公司 一种用于直接压片制备口崩片的预混辅料
CN108348616B (zh) * 2015-09-30 2022-12-23 株式会社大赛璐 易服用性固体制剂用颗粒组合物和包含该颗粒组合物的易服用性固体制剂
CN105435237B (zh) * 2015-12-17 2018-12-28 河南润弘制药股份有限公司 一种盐酸普拉格雷药物组合物，片剂及其制备方法
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
CN107536816A (zh) * 2016-06-29 2018-01-05 康普药业股份有限公司 一种甲硝唑制剂
KR20220144885A (ko) 2016-08-05 2022-10-27 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법
TWI777515B (zh) 2016-08-18 2022-09-11 美商愛戴爾製藥股份有限公司 治療嗜伊紅性食道炎之方法
US20190247296A1 (en) * 2016-09-02 2019-08-15 Nova Southeastern University Atropine sulfate rapidly-disintegrating sublingual tablets of improved formulation, methods for manufacture thereof, and methods for use thereof for treatment of acute organophosphate toxicity
JP7090616B2 (ja) * 2016-12-14 2022-06-24 エスケー バイオファーマスティカルズ カンパニー リミテッド カルバメート化合物を含む口腔内崩壊錠
US10350171B2 (en) 2017-07-06 2019-07-16 Dexcel Ltd. Celecoxib and amlodipine formulation and method of making the same
WO2019071272A1 (en) 2017-10-06 2019-04-11 Adare Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY (ADHD)
WO2019071270A1 (en) 2017-10-06 2019-04-11 Adare Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS
KR20210002478A (ko) * 2018-04-17 2021-01-08 주식회사 다이셀 복용 용이성 과립제 및 그 제조 방법
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
JP6858729B2 (ja) * 2018-05-25 2021-04-14 ▲財▼▲団▼法人国防教育研究基金会Ｎａｔｉｏｎａｌ Ｄｅｆｅｎｓｅ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ 肝臓に対する副作用がない、新しいアセトアミノフェン複合組成
CN109330993A (zh) * 2018-11-26 2019-02-15 正大制药（青岛）有限公司 一种盐酸环苯扎林缓释胶囊及其制备方法
CN109730967B (zh) * 2019-02-19 2021-08-03 广东工业大学 一种硝苯地平固体分散体及其制备方法
WO2020212958A1 (en) * 2019-04-18 2020-10-22 Tatawati Shivanand Cleansing/sanitizer compositions, methods and applications thereof
US20210346257A1 (en) * 2020-05-08 2021-11-11 Fertin Pharma A/S Oral Powder Mixture With Small Sized Particles
CA3178769A1 (en) 2020-05-18 2021-11-25 Jonas Savmarker New pharmaceutical composition for drug delivery
MX2023000649A (es) * 2020-07-15 2023-02-23 Bio Bond Llc Adhesivo de estabilizacion de tarima.
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
TW202228665A (zh) 2020-10-05 2022-08-01 凱瑞康寧生技股份有限公司 γ－羥基丁酸衍生物之修飾釋放組合物
CN112137097A (zh) * 2020-10-10 2020-12-29 广东青云山药业有限公司 一种口腔速溶颗粒及其制备方法
US11452690B1 (en) 2021-01-27 2022-09-27 ECI Pharmaceuticals, LLC Oral liquid compositions comprising amlodipine besylate and methods of using the same
TW202300139A (zh) 2021-03-19 2023-01-01 凱瑞康寧生技股份有限公司 γ-羟基丁酸衍生物的聯合釋放製劑的藥代動力學
WO2023012162A1 (en) 2021-08-03 2023-02-09 Dfe Pharma Gmbh & Co. Kg. Method for preparing co-processed excipient granules
US20230123099A1 (en) * 2021-10-15 2023-04-20 Fertin Pharma A/S Dextrose tablets with improved mouthfeel
AR127780A1 (es) 2021-11-25 2024-02-28 Orexo Ab Nueva composición farmacéutica que comprende adrenalina
US20230321116A1 (en) * 2022-02-16 2023-10-12 Lipocine Inc. 3Alpha-OH-5Beta-Pregnan-20-One Compositions and Methods for Treating Central Nervous System Disorders

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2556561C2 (de) 1975-12-16 1983-04-14 Boehringer Mannheim Gmbh, 6800 Mannheim Verfahren zur Herstellung von porösen Tabletten
CA1097233A (en) 1977-07-20 1981-03-10 George K. E. Gregory Packages
FR2561916B1 (fr) 1984-03-30 1987-12-11 Lafon Labor Forme galenique pour administration orale et son procede de preparation par lyophilisation d'une emission huile dans eau
US5079018A (en) 1989-08-14 1992-01-07 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5039540A (en) 1989-08-14 1991-08-13 Neophore Technologies, Inc. Freeze dry composition and method for oral administration of drugs, biologicals, nutrients and foodstuffs
US5178878A (en) 1989-10-02 1993-01-12 Cima Labs, Inc. Effervescent dosage form with microparticles
US5215756A (en) 1989-12-22 1993-06-01 Gole Dilip J Preparation of pharmaceutical and other matrix systems by solid-state dissolution
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
NZ246091A (en) 1991-12-24 1995-08-28 Yamanouchi Pharma Co Ltd Intrabuccally disintegrating preparation containing an active ingredient, agar, and lactose and/or mannitol
JP3069458B2 (ja) 1992-01-29 2000-07-24 武田薬品工業株式会社 口腔内崩壊型錠剤およびその製造法
US5298261A (en) 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
US5843347A (en) 1993-03-23 1998-12-01 Laboratoire L. Lafon Extrusion and freeze-drying method for preparing particles containing an active ingredient
US5576014A (en) 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5738875A (en) 1994-10-28 1998-04-14 R.P. Scherer Corporation Process for preparing solid pharmaceutical dosage forms
US8071128B2 (en) 1996-06-14 2011-12-06 Kyowa Hakko Kirin Co., Ltd. Intrabuccally rapidly disintegrating tablet and a production method of the tablets
ES2296331T3 (es) 1997-04-01 2008-04-16 Cima Labs Inc. Envase de tipo blister y comprimido envasado.
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
EP1107911B1 (en) 1998-03-09 2005-01-19 Cima Labs Inc. Apparatus for handling and packaging friable tablets
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
JP2000095674A (ja) 1998-09-22 2000-04-04 Sato Pharmaceutical Co Ltd 口腔内崩壊時間短縮化錠剤の製造方法及び装置
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
ATE432692T1 (de) 2001-03-06 2009-06-15 Kyowa Hakko Kirin Co Ltd Tabletten, die in der mundhöhle schnell zerfallen
US6500454B1 (en) 2001-10-04 2002-12-31 Eurand Pharmaceuticals Ltd. Timed, sustained release systems for propranolol
US6663888B2 (en) 2001-12-14 2003-12-16 Eurand Pharmaceuticals Ltd. Pulsatile release histamine H2 antagonist dosage form
JP4408340B2 (ja) * 2002-03-22 2010-02-03 武田薬品工業株式会社 速崩壊性固形製剤
US20050147670A1 (en) 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US20040121003A1 (en) * 2002-12-19 2004-06-24 Acusphere, Inc. Methods for making pharmaceutical formulations comprising deagglomerated microparticles
US20050014767A1 (en) * 2003-01-29 2005-01-20 Magnus Pfahl Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
US7347553B2 (en) * 2004-09-24 2008-03-25 Canon Kabushiki Kaisha Ophthalmic image sensing apparatus
US9884014B2 (en) 2004-10-12 2018-02-06 Adare Pharmaceuticals, Inc. Taste-masked pharmaceutical compositions
CA2584957C (en) 2004-10-21 2015-08-25 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions with gastrosoluble pore-formers
US20060105038A1 (en) 2004-11-12 2006-05-18 Eurand Pharmaceuticals Limited Taste-masked pharmaceutical compositions prepared by coacervation
WO2006085497A1 (ja) * 2005-02-09 2006-08-17 Kissei Pharmaceutical Co., Ltd. 口腔内崩壊錠
WO2006085625A1 (ja) * 2005-02-10 2006-08-17 Soshin Electric Co., Ltd. 電子部品
BRPI0707324A2 (pt) 2006-01-27 2011-05-03 Eurand Inc sistemas de fornecimento de fármaco compreendendo agente de bloqueio de serotonina 5-ht3 seletivo fracamente básico e ácidos orgánicos
NZ569984A (en) 2006-01-27 2011-06-30 Eurand Inc Drug delivery systems comprising weakly basic drugs and organic acids
US20080069878A1 (en) 2006-08-31 2008-03-20 Gopi Venkatesh Drug Delivery Systems Comprising Solid Solutions of Weakly Basic Drugs
JP4034330B1 (ja) 2006-09-20 2008-01-16 タイコエレクトロニクスアンプ株式会社 回路ユニット収容ボックス
BRPI0808889A2 (pt) * 2007-03-13 2014-11-11 Dainippon Sumitomo Pharma Co Comprimido desintegrante oral
TWI547282B (zh) * 2007-07-02 2016-09-01 愛戴爾製藥股份有限公司 樂命達之口服分解錠劑組合物
CN101951767A (zh) 2007-12-10 2011-01-19 欧兰德股份有限公司 包含苯海拉明的口服崩解片剂
AR069875A1 (es) * 2007-12-21 2010-02-24 Eurand Inc Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
WO2009102830A1 (en) 2008-02-13 2009-08-20 Eurand Inc Orally disintegrating tablet compositions of ranitidine and methods of manufacture
US8133506B2 (en) 2008-03-12 2012-03-13 Aptalis Pharmatech, Inc. Drug delivery systems comprising weakly basic drugs and organic acids
TWI519322B (zh) 2008-04-15 2016-02-01 愛戴爾製藥股份有限公司 包含弱鹼性藥物及控制釋放劑型之組合物
US7663062B1 (en) 2008-07-30 2010-02-16 Himax Technologies Limited Flexible circuit board
CN108969490A (zh) 2010-12-02 2018-12-11 艾戴尔医药公司 快速分散颗粒、口腔崩解片以及方法

Also Published As

Publication number Publication date
CO6781487A2 (es) 2013-10-31
ZA201304894B (en) 2014-09-25
JP6014044B2 (ja) 2016-10-25
AU2011336300A1 (en) 2013-05-02
ES2813859T3 (es) 2021-03-25
MX365568B (es) 2019-06-07
US20120282335A1 (en) 2012-11-08
KR101965002B1 (ko) 2019-08-13
KR20140001236A (ko) 2014-01-06
WO2012075455A3 (en) 2013-06-27
CN103402497A (zh) 2013-11-20
CL2013001586A1 (es) 2013-11-29
EP2646003B1 (en) 2020-06-03
NZ611467A (en) 2015-06-26
AU2011336300B2 (en) 2015-05-21
CA2819663C (en) 2019-12-24
CN107028900A (zh) 2017-08-11
CA2819663A1 (en) 2012-07-06
EP2646003A4 (en) 2016-08-03
CN108969490A (zh) 2018-12-11
WO2012075455A2 (en) 2012-06-07
RU2013127593A (ru) 2015-01-10
SG190448A1 (en) 2013-07-31
JP2013544849A (ja) 2013-12-19
EP2646003A2 (en) 2013-10-09

Similar Documents

Publication Publication Date Title
SG190448A1 (en) Rapidly dispersing granules, orally disintegrating tablets and methods
WO2014096388A3 (en) Novel benzimidazole derivatives as kinase inhibitors
WO2009063222A3 (en) Solid compositions
GB0906579D0 (en) Pharmaceuticals, compositions and methods of making and using the same
WO2011041729A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011017350A3 (en) Compounds as lysophosphatidic acid receptor antagonists
WO2011121418A9 (en) 4 - aminopyrimidine derivatives and their as as adenosine a2a receptor antagonists
WO2011041462A3 (en) Polycyclic compounds as lysophosphatidic acid receptor antagonists
UA110310C2 (uk) Сполуки n-арилтриазолу як антагоністи рецепторів лізофосфатидної кислоти (lpar)
WO2012032209A3 (es) Uso de un agonista de trpm8 para la elaboración de un medicamento para el tratamiento de xeroftalmia, sequedad vaginal y síndrome de la boca seca y uso de un antagonista de trpm8 para la elaboración de un medicamento pra el tratamiento de la epífora.
WO2010077883A3 (en) Antagonists of lysophosphatidic acid receptors
WO2010141761A3 (en) Polycyclic antagonists of lysophosphatidic acid receptors
NO20084931L (no) Farmasoytiske sammensetninger
MY161127A (en) Enhanced soluble c5 saccharide yields
WO2012088266A3 (en) Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
MY159208A (en) A novel formulation of indomethacin
WO2011110939A3 (en) Pharmaceutical compositions of substituted benzhydrylpiperazines
WO2011146583A3 (en) Nanoparticulate cinacalcet formulations
IT1404931B1 (it) Composizioni oftalmiche per la somministrazione di principi attivi liposolubili .
WO2012073170A3 (fr) Composition galénique adaptée à l'administration à un animal non-humain, utilisations de celle-ci et méthodes associées
MX344109B (es) Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico.
WO2015034678A3 (en) Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
WO2008049633A3 (en) Spray-freeze-drying process for the preparation of pellets comprising percolation drying
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: COATINGS FOREIGN IP CO. LLC.*

FG Grant or registration